

**IND Number 27073**  
**Sequence No. 0012**

December 11, 2020

Marion Gruber, PhD  
Director, Office of Vaccines Research and Review  
Center for Biologics Evaluation and Research  
U.S. Food and Drug Administration  
Document Control Center  
10903 New Hampshire Avenue  
WO71, G112  
Silver Spring, MD 20993-0002

**Submission Type: CMC - Response to Comments Regarding FDA Requests (IR #12)**

Dear Dr. Gruber:

Reference is made to pre-assigned submission tracking number (STN) EUA 27073 for Emergency Use Authorization of the new drug mRNA-1273.

The purpose of this submission is to support the Emergency Use Authorization Request submitted on 30 November 2020 for mRNA-1273, a novel lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA)-based vaccine against the 2019 novel coronavirus (CoV; SARS-CoV-2).

This submission includes:

1.2 Cover Letter

1.11.3 Response to Comments regarding FDA Requests IR#12

If FDA has any questions, please do not hesitate to contact me directly at (b) (6) or at (b) (6)@modernatx.com.

This eCTD submission has been prepared by PPD Development, Inc. in full compliance with ICH and FDA guidance. The eCTD has been verified and confirmed to be virus and spyware free. PPD utilizes Palo Alto Traps v4.2.2. All technical questions should be directed to (b) (6) at PPD (b) (6) or email at (b) (6)

Yours Sincerely,

**Carla**  
**Vinals**  
Digitally signed  
by Carla Vinals  
Date:  
2020.12.11  
16:26:32 -05'00'

Carlota Vinals  
VP, Regulatory Affairs Strategy  
ModernaTX, Inc.



200 Technology Square • Cambridge, MA 02139  
phone 617-714-6500 • fax 617-649-3744

200 Technology Square  
Cambridge, MA 02139

Tel.: (b) (6); Fax: (b) (6)

Email: (b) (6)@modernatx.com